Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 11/12/25 | 425 | Prospectuses and communications, business combinations |
|
28 | |
| 10/27/25 | 424B3 | Prospectus [Rule 424(b)(3)] |
|
507 | |
| 10/27/25 | DEFM14A | Definitive proxy statement relating to merger or acquisition |
|
510 | |
| 10/22/25 | S-1 | General form for registration of securities under the Securities Act of 1933 |
|
  |
352 |
| 10/06/25 | S-4/A | Registration of securities, business combinations |
|
|
526 |
| 09/29/25 | 8-K | Current report |
|
|
2 |
| 09/22/25 | S-4/A | Registration of securities, business combinations |
|
|
555 |
| 09/04/25 | S-4 | Registration of securities, business combinations |
|
|
517 |
| 08/26/25 | ARS | Annual Report to Security Holders |
|
134 | |
| 08/26/25 | DEF 14A | Definitive proxy statements |
|
|
32 |
